The global pediatric obesity management market is poised for significant growth, with an expected market value of USD 3.2 Billion in 2023. As the prevalence of childhood obesity continues to rise globally, the market is projected to expand at a compound annual growth rate (CAGR) of 4%, reaching an estimated value of USD 4.74 Billion by 2033.
Pediatric obesity has become a critical public health issue, with long-term implications for children’s overall health. As the condition becomes more prevalent, there is an increasing demand for effective management strategies, which is driving the market’s growth. In the historical period from 2018 to 2022, the market recorded a CAGR of 3%, reflecting the growing awareness and need for intervention.
The Pediatric Obesity Management market offers a comprehensive range of products and services aimed at providing effective treatment and management for this growing concern. Key offerings include lifestyle modifications, behavioral therapy, medications, and bariatric surgery, all of which are tailored to address the unique challenges of managing obesity in children. These treatments not only help in controlling the condition but also play a pivotal role in improving the overall health and well-being of affected children.
Healthcare providers, along with parents and caregivers, are increasingly adopting a multi-faceted approach to pediatric obesity management, combining both medical and lifestyle interventions to ensure long-term success. With a focus on holistic care, the market is expected to continue its upward trajectory, offering innovative and personalized solutions to combat childhood obesity.
As the market evolves, there is a growing emphasis on developing new treatment options and strategies that will further enhance the effectiveness of managing pediatric obesity. The global Pediatric Obesity Management Market is set to play a crucial role in combating one of the most pressing health issues facing children today.
Key Takeaways from the Market Study:
- The market for paediatric obesity management expanded at a CAGR of 3% between 2018 and 2022.
- From 2023 to 2033, the global market for paediatric obesity management is anticipated to expand at a 4% CAGR.
- The Pediatric Obesity Management Market is anticipated to generate USD 4.74 billion by 2033.
- According to the FMI analysis, hospital pharmacies account for the largest market share.
- In terms of market share for paediatric obesity management, North America is predicted to hold 40% of the market.
- With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Pediatric Obesity Management.” says an FMI analyst
Surge in Market Demand: Explore Comprehensive Trends and Analysis in Our Full Report!
Market Competition:
Key players in the market include companies such as Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., AstraZeneca, Herbalife Ltd., Apollo Endosurgery, Ethicon, Inc., Takeda Pharmaceutical Company, VIVUS Inc., Currax Pharmaceuticals LLC, along with healthcare providers and technology companies among other global players.
- The U.S. Food and Drug Administration approved the use of Wegovy (semaglutide) injection (2.4 mg once weekly) as a medication for chronic weight control in individuals with obesity or those who are overweight with at least one weight-related disease, such as high blood pressure, high cholesterol, or type 2 diabetes, in June 2021. The medication can be taken along with a lower calorie diet and more exercise. Since 2014, this subcutaneous injection is the first medication to be licenced for managing chronic weight in individuals who are obese or overweight. Patients with a body mass index (BMI) of 27 kg/m2 or above who have at least one weight-related condition, as well as those with a BMI of 30 kg/m2 or more, are advised to use it.
Key Segments Profiled in the Pediatric Obesity Management Industry Survey:
Drug Class:
- Lorcaserin
- Liraglutide
- Phentermine
- Setmelanotide
- Others
Route of Administration:
- Oral
- Injectable
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube